Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Iwamura R., Tanaka M., Okanari E., Kirihara T., Odani-Kawabata N., Shams N., Yoneda K.

2018
Journal of Medicinal Chemistry

Therapeutic Area

Glaucoma
Technology

Other
Categories

Preclinical development

Affiliations

Pharmaceuticals Research Laboratory, UBE Industries, Ltd., 1978-5 Kogushi, Ube Yamaguchi, 755-8633, Japan; R and D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A 4-20, Ofukacho, Kita-ku. Osaka, 530-8552, Japan; R and D Division, Santen Inc., 6401 Hollis Street, Emeryville, CA 94608, United States

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications